Although blocking TGFβ signaling is widely viewed as a promising anti-tumor strategy, efforts in GBM have mainly focused on blocking TGFBR1 activity without successful clinical translation [56,57,58]. This evidence concerns the gene TGFBR1 and neoplasm.